

Akihiro Ohmoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4139627/publications.pdf>

Version: 2024-02-01

46
papers

540
citations

759233

12
h-index

713466

21
g-index

50
all docs

50
docs citations

50
times ranked

1093
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Pazopanib-Related Heart Failure in Patients With Advanced Soft Tissue Sarcoma—A Single Institute Analysis. <i>Circulation Journal</i> , 2024, 88, 228-233.	1.6	1
2	A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients. <i>Endocrine</i> , 2022, 76, 70-77.	2.3	2
3	Novel antibodies which have an impact on immune status after allogeneic hematopoietic cell transplantation. <i>Expert Review of Hematology</i> , 2022, , 1-7.	2.2	0
4	Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 874-880.	2.4	3
5	Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis. <i>Discover Oncology</i> , 2022, 13, .	2.1	3
6	Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16217-e16217.	1.6	0
7	Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 3037-3043.	1.6	4
8	Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL. <i>Blood Reviews</i> , 2021, 46, 100738.	5.7	9
9	Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. <i>Cancer Reports</i> , 2021, 4, e1322.	1.4	4
10	Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. <i>Endocrine Journal</i> , 2021, 68, 1383-1390.	1.6	3
11	Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma. <i>Anticancer Research</i> , 2021, 41, 527-532.	1.1	6
12	Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy-intolerant lymphoma patients. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 715-722.	2.4	1
13	Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib. <i>Anticancer Research</i> , 2021, 41, 1683-1691.	1.1	7
14	Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma. <i>Modern Pathology</i> , 2021, 34, 1979-1989.	5.5	17
15	Cardiac complications associated with hematopoietic stem-cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2637-2643.	2.4	11
16	Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders. <i>Blood Reviews</i> , 2021, 49, 100807.	5.7	7
17	Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer. <i>In Vivo</i> , 2021, 35, 1211-1215.	1.3	14
18	Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy. <i>Endocrine Journal</i> , 2021, 68, 671-681.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of 8 weeks ^â ™ relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients. <i>Endocrine Journal</i> , 2021, 68, 639-647.	1.6	9
20	Current status of drug repositioning in hematology. <i>Expert Review of Hematology</i> , 2021, 14, 1005-1011.	2.2	0
21	Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma. <i>Cancer Diagnosis & Prognosis</i> , 2021, 1, 303-308.	0.7	4
22	Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 8377-8385.	1.9	9
23	Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. <i>Cancers</i> , 2021, 13, 6266.	3.7	9
24	Histological transformation in malignant lymphoma: a possible role of PET/CT and circulating tumor DNA as noninvasive diagnostic tools. <i>Expert Review of Hematology</i> , 2020, 13, 23-30.	2.2	4
25	Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib. <i>In Vivo</i> , 2020, 34, 2859-2864.	1.3	17
26	<p>Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4161-4168.	1.9	17
27	Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	15
28	Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms. <i>Current Drug Targets</i> , 2020, 21, 389-405.	2.1	1
29	Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line. <i>Molecular and Clinical Oncology</i> , 2020, 14, 13.	1.0	6
30	An extragonadal germ cell tumor with dermatomyositis: A case report and literature review. <i>Molecular and Clinical Oncology</i> , 2020, 13, 60.	1.0	1
31	An extragonadal germ cell tumor with dermatomyositis: A case report and literature review. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	1.0	2
32	Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. <i>Expert Review of Hematology</i> , 2019, 12, 975-981.	2.2	13
33	Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 561.	4.1	32
34	Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. <i>Journal of Gastroenterology</i> , 2018, 53, 1159-1167.	5.1	7
35	Double-hit and double-expressor B-cell lymphomas: Current treatment strategies and impact of hematopoietic cell transplantation. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e13.	0.9	2
36	Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma. <i>Oncotarget</i> , 2018, 9, 21086-21099.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Association between pretransplant iron overload determined by bone marrow pathological analysis and bacterial infection. <i>Bone Marrow Transplantation</i> , 2017, 52, 1201-1203.	2.4	9
38	Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. <i>International Journal of Molecular Sciences</i> , 2017, 18, 143.	4.1	49
39	Current status of poly(ADP-ribose) polymerase inhibitors and future directions. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5195-5208.	2.0	96
40	Clinicopathologic Features and Germline Sequence Variants in Young Patients (≤ 40 Years Old) With Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2016, 45, 1056-1061.	1.1	20
41	Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation. <i>Journal of Hematopoietic Cell Transplantation</i> , 2016, 5, 93-101.	0.1	0
42	Germline mutations in Japanese familial pancreatic cancer patients. <i>Oncotarget</i> , 2016, 7, 74227-74235.	1.8	62
43	Histopathological analysis of B-cell non-Hodgkin lymphomas without light chain restriction by using flow cytometry. <i>Leukemia and Lymphoma</i> , 2015, 56, 3301-3305.	1.3	14
44	Clinical features of young patients (below age 40) with pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 199-199.	1.6	0
45	Second morning urine method is superior to the casual urine method for estimating daily salt intake in patients with hypertension. <i>Hypertension Research</i> , 2012, 35, 611-616.	2.7	28
46	Anti-prion activity of protein-bound polysaccharide K in prion-infected cells and animals. <i>Biochemical and Biophysical Research Communications</i> , 2011, 405, 285-290.	2.1	14